Exclusive Market Insight & Professional Analysis: The most comprehensive resource center for the biotech industry

        Sign Up Today! Get started for all the insight you want!
  • Exclusive Posts

  • Industry Newsletters

  • Clinical Trials

  • Therapeutic Vaccines

  • Development-Stage Firm

  • Genomics

  • Gene Analysis

  • RNA Analysis

  • Possible Approvals

  • Stock Table

  • Possible Takeovers

  • Technology of the Week

  • Prohost Picks

  • And much more...

BIOTECHNOLOGY NEWS & COMMENTS

Moderna Is a Private Revolutionary Biotech Firm That Investors Should Not Ignore

  Tuesday, July 26, 2016

We love to present to you Moderna, a firm that, we believe, is building revolutionary pipeline products. We mean it when we say revolutionary. The time has come for Moderna to be heard of by serious investors. It is still private, but it is revolutionary and is working with the publicly-traded firms AstraZeneca (AZN), Merck (MRK), and Vertex (VRTX) to bring what we believe will be game changing approaches for the management of intractable, untreatable and deadly diseases.   More...

NOVOCURE: The FDA Approves the Firm's Second Generation Non-Invasive Treatment for Glioblastoma

  Friday, July 15, 2016

News about approvals or insinuations about almost guaranteed future approvals of products that promise improving the management of chronic and life-threatening diseases are always welcomed with enthusiasm. Of course some approvals are more rewarding than others, which has to be assessed by investors. For the patients, however, any improvement, small or phenomenal is always considered good news.  More...

JUNO Surged After the FDA Removed the Clinical Hold of the ROCKET Trial. See Also: Why SAGE Surged

  Wednesday, July 13, 2016

JUNO   More...

Biotech Firms with Guaranteed Growth Potential

  Thursday, July 07, 2016

Good news is not always great news that makes a difference. In the drug industry, clinical trial results that demonstrate a drug has fulfilled the requirements of the trials, including the primary and secondary endpoints does not always guarantee that the drug will be successful if and when it hits the market. Experience and follow up on certain firms enables us to see the real light at the end of the tunnel, not just celebrate reaching the end of it without knowing what to expect outside. This makes a big difference.  More...

The Royal Divorce. Gilead Rallied Not Plummeted

  Wednesday, June 29, 2016

The Royal Divorce More...

The Biotech Sector Evolution in the News

  Wednesday, June 22, 2016

Innoviva (INVA) and GlaxoSmithKline plc (GSK) announced positive results from the pivotal Phase 3 FULFIL study of the Closed Triple combination of fluticasone furoate, umeclidinium, and vilanterol) for patients with chronic obstructive pulmonary disease (COPD).  More...

SPARK Therapeutics History Foretells Its Triumph in Gene Therapy

  Thursday, June 16, 2016

SPARK More...

Good News for Agenus and for Global Blood Therapeutics

  Friday, June 10, 2016

Agenus (AGEN) announced that a lead product candidate is selected under its license and research collaboration with Merck, which is known as MSD outside the United States and Canada.   More...

Biomarin Decision Might Add More Stress Than Put Pressure on the FDA to Approve Sarepta Drug

  Thursday, June 02, 2016

Biomarin Pharmaceutical’s (BMRN) decision to withdraw its DMD drug Kyndrisa™ (drisapersen) Marketing Authorization Application (MAA) from the European Medicines Agency (EMA) means more than pressuring the FDA to approve Sarepta’s DMD product eteplirsen.  More...

IONIS Stock Selloff: Has GSK Abandoned the Wagon or Jumped Out of the Train? See Also: Osteoporosis

  Friday, May 27, 2016

 More...

Join our FREE Email Updates, with the latest insight information about the biotech industry